90%Confidence
0Views
FDASource
2026-03-06Date
Summary
Asteria Health's estradiol product recall extends contamination concerns to hormone replacement therapies, indicating cross-product manufacturing failures. This could create supply shortages for patients dependent on pellet-based hormone therapies.
Actionable: Identify alternative estradiol pellet suppliers and alert healthcare providers about recall implications.
AI Confidence: 90%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productESTRADIOL, 25 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-3025-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now